Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in adults and adolescents with severe hemophilia A

被引：0
|
作者：
Konkle, Barbara A. [1 ]
Pasi, K. John [2 ]
Perry, David J. [3 ]
Mahlangu, Johnny [4 ]
Rangarajan, Savita [5 ]
Hanabusa, Hideji [6 ]
Pabinger, Ingrid [7 ]
Lethagen, Stefan [8 ,9 ]
Cristiano, Lynda M. [10 ]
Yuan, Huixing [10 ]
Pierce, Glenn F. [10 ]
Allen, Geoffrey [10 ]
机构：
[1] Bloodworks Northwest, Seattle, WA USA
[2] Barts & London Comprehens Care Ctr, London, England
[3] Addenbrookes Hosp, Cambridge, England
[4] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
[5] Hampshire Hosp NHS Trust, Basingstoke, Hants, England
[6] Ogikubo Hosp, Tokyo, Japan
[7] Med Univ Wien, Vienna, Austria
[8] Sobi, Stockholm, Sweden
[9] Univ Copenhagen, Copenhagen, Denmark
[10] Biogen, Cambridge, MA USA
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [11] Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study
    Pasi, J.
    Perry, D.
    Mahlangu, J.
    Konkle, B.
    Rangarajan, S.
    Brown, S. A.
    Hanabusa, H.
    Jackson, S.
    Pabinger-Fasching, I.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2015, 21 : 52 - 53
  • [12] Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a
    Wang, Michael
    Pasi, K. John
    Pabinger, Ingrid
    Kerlin, Bryce A.
    Kulkarni, Roshni
    Nolan, Beatrice
    Liesner, Raina
    Brown, Simon A.
    Hanabusa, Hideji
    Tsao, Elisa
    Winding, Bent
    Lethagen, Stefan
    Jain, Nisha
    BLOOD, 2016, 128 (22)
  • [13] Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
    Krishnamoorthy, Sriram
    Liu, Tongyao
    Drager, Douglas
    Patarroyo-White, Susannah
    Chhabra, Ekta Seth
    Peters, Robert
    Josephson, Neil
    Lillicrap, David
    Blumberg, Richard S.
    Pierce, Glenn F.
    Jiang, Haiyan
    CELLULAR IMMUNOLOGY, 2016, 301 : 30 - 39
  • [14] PERIOPERATIVE MANAGEMENT OF PATIENTS WITH SEVERE HAEMOPHILIA A WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)
    Bocchinfuso, S.
    O'Donovan, M.
    Singleton, E.
    Benson, J.
    Byrne, M.
    Ryan, K.
    O'Donnell, J. S.
    O'Connell, N. M.
    HAEMOPHILIA, 2021, 27 : 105 - 106
  • [15] Long-Term Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFC) Prophylaxis in Paediatric, Adolescent, and Adult Subjects with Target Joints and Severe Haemophilia A
    Pasi, K. J.
    Pabinger, I.
    Kerlin, B. A.
    Kulkarni, R.
    Nolan, B.
    Wang, M.
    Liesner, R.
    Brown, S. A.
    Hanabusa, H.
    Tsao, E.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 21 - 21
  • [16] Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A
    Mahlangu, Johnny N.
    Ragni, Margaret
    Gupta, Naresh
    Rangarajan, Savita
    Klamroth, Robert
    Oldenburg, Johannes
    Nogami, Keiji
    Young, Guy
    Cristiano, Lynda M.
    Dong, Yingwen
    Allen, Geoffrey
    Pierce, Glenn F.
    Robinson, Brian
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (01) : 1 - 8
  • [17] Longitudinal modified hemophilia joint health scores (mHJHS) outcomes with recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in subjects with severe hemophilia A
    Oldenburg, Johannes
    Kulkarni, Roshni
    Srivastava, Alok
    Mahlangu, Johnny
    Lethagen, Stefan
    Tsao, Elisa
    Jain, Nisha
    HAEMOPHILIA, 2016, 22 : 40 - 40
  • [18] Recombinant factor VIII Fc fusion protein (rFVIIIFc) efficacy for perioperative haemostatic management in severe haemophilia A
    Ragni, M. V.
    Chowdary, P.
    Pabinger, I.
    Feng, J.
    Lethagan, S.
    Barnowski, C.
    Mahlangu, J. N.
    HAEMOPHILIA, 2019, 25 : 9 - 9
  • [19] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [20] Second Interim Analysis of the Aspire Study Evaluating Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A
    Nolan, B.
    Young, G.
    Mahlangu, J.
    Liesner, R.
    Pasi, K. J.
    Lethagen, S.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 65 - 66
12345